Kisspeptin: Molecular Structure

Molecular Structure and Properties#

Kisspeptin is not a single peptide but a family of biologically active fragments derived from the proteolytic processing of the 145-amino acid KISS1 gene product. The full-length mature peptide, kisspeptin-54 (KP-54, formerly called metastin), has a molecular weight of approximately 5861.5 Da and the molecular formula C257H383N69O74S3. Shorter fragments including kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and kisspeptin-10 (KP-10) are generated through further endoproteolytic cleavage at dibasic or monobasic sites within the N-terminal region of KP-54. All biologically active kisspeptin isoforms share an identical C-terminal decapeptide sequence and signal through the same receptor, KISS1R.

The CAS registry number for kisspeptin-54 is 374675-21-5. The KISS1 gene is located on chromosome 1q32 in humans and was originally identified in 1996 as a metastasis suppressor gene in melanoma, hence the historical name "metastin" for KP-54.

Amino Acid Sequence#

Kisspeptin-10 (KP-10) Primary Sequence#

The minimal bioactive fragment of kisspeptin is the C-terminal decapeptide, kisspeptin-10:

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2

Single-letter code: YNWNSFGLRF-NH2

KP-10 retains full receptor-binding activity at KISS1R and is the smallest fragment sufficient for complete receptor activation. The C-terminal amidation (Phe-NH2) is essential for biological activity, as the free acid form shows markedly reduced receptor binding affinity.

Kisspeptin-54 (KP-54) Full-Length Sequence#

The full 54-amino acid mature peptide represents the complete processed form of the KISS1 precursor after signal peptide cleavage and C-terminal processing. KP-54 includes the entire N-terminal extension upstream of the conserved decapeptide motif.

Isoform Comparison#

All isoforms activate KISS1R with comparable efficacy because receptor recognition depends on the shared C-terminal RF-amide motif rather than the N-terminal extension. However, KP-54 has a longer circulating half-life than shorter isoforms due to reduced susceptibility to exopeptidase degradation.

C-Terminal RF-Amide Motif#

The defining structural feature of all kisspeptin isoforms is the C-terminal Arg-Phe-NH2 (RF-amide) motif. This places kisspeptins within the broader RF-amide peptide superfamily, which includes neuropeptide FF (NPFF), prolactin-releasing peptide (PrRP), QRFP/26RFa, and gonadotropin-inhibitory hormone (GnIH/RFRP-3). Each RF-amide peptide signals through its own cognate GPCR, though some cross-reactivity exists at high concentrations.

The RF-amide motif is the primary pharmacophore for KISS1R binding. Structure-activity relationship studies have established the following key points regarding the C-terminal region:

• The terminal Phe-NH2 is indispensable; replacement with free acid (Phe-OH) or other residues dramatically reduces binding
• The Arg at position -2 from the C-terminus contributes to electrostatic interactions with the receptor binding pocket
• The Leu at position -3 provides hydrophobic contacts that stabilize the peptide-receptor complex
• Substitution of Gly at position -4 alters the backbone flexibility required for optimal receptor engagement

KISS1 Gene Product Processing#

The KISS1 gene encodes a 145-amino acid precursor protein. The biosynthetic pathway proceeds through several processing steps:

1. Signal peptide cleavage: The N-terminal signal sequence (approximately 19 amino acids) is removed during translocation into the endoplasmic reticulum, yielding a 126-amino acid propeptide.

2. Furin/proprotein convertase cleavage: The propeptide is cleaved at dibasic residue sites by furin-like proprotein convertases in the trans-Golgi network and secretory granules. This generates the 54-amino acid mature kisspeptin-54 peptide.

3. C-terminal amidation: The C-terminal glycine-extended intermediate is processed by peptidylglycine alpha-amidating monooxygenase (PAM) to generate the biologically critical Phe-NH2 terminus. This amidation step is required for receptor binding activity.

4. Further proteolysis: Extracellular or intracellular peptidases can generate the shorter KP-14, KP-13, and KP-10 isoforms through cleavage at sites within the N-terminal region of KP-54. The extent to which these shorter fragments are produced physiologically versus as degradation products remains an area of investigation.

Chemical Properties#

Receptor Binding and Signaling#

Kisspeptin binds to KISS1R (formerly designated GPR54), a seven-transmembrane Gq/11-coupled G-protein coupled receptor. KISS1R belongs to the rhodopsin family of GPCRs and is most closely related to galanin receptors in sequence, although kisspeptin does not bind galanin receptors.

Upon kisspeptin binding, KISS1R activates Gq/11 signaling, leading to phospholipase C-beta (PLC-beta) activation and hydrolysis of PIP2 into IP3 and DAG. This triggers intracellular calcium release and PKC activation, which are the primary effectors mediating GnRH neuron depolarization. Additional downstream pathways include MAPK/ERK1/2, p38 MAPK, and PI3K/Akt cascades. In GnRH neurons specifically, kisspeptin also activates TRPC (transient receptor potential canonical) channels, contributing to sustained depolarization.

KISS1R undergoes beta-arrestin-mediated internalization upon sustained agonist exposure, leading to receptor desensitization. This desensitization is clinically significant because continuous kisspeptin exposure results in an initial stimulation followed by suppression of GnRH release, analogous to the paradoxical suppressive effect seen with continuous GnRH agonist administration.

Metabolism and Half-Life#

Kisspeptin-54 has a circulating half-life of approximately 28 minutes following intravenous administration in humans. The shorter isoforms are degraded more rapidly; kisspeptin-10 has an estimated half-life of less than 4 minutes intravenously, owing to its greater susceptibility to amino- and carboxypeptidases.

The primary degradation pathways involve:

• Matrix metalloproteinase-mediated cleavage: MMP-2 and MMP-9 have been identified as major kisspeptin-degrading enzymes, cleaving within the central region of KP-54 and inactivating the peptide
• Exopeptidase degradation: Aminopeptidases and carboxypeptidases progressively trim residues from both termini, with shorter isoforms being more vulnerable due to the proximity of the critical C-terminal RF-amide motif to the cleavage sites
• Renal clearance: Kisspeptin is filtered by the kidneys and contributes to urinary elimination

The rapid metabolism necessitates parenteral administration (subcutaneous or intravenous) for all clinical applications. In the IVF trigger context, the single bolus subcutaneous injection of KP-54 produces a sufficiently prolonged endogenous GnRH and LH surge despite the relatively short peptide half-life, because the downstream hormonal cascade (GnRH release, LH secretion, and ovarian response) amplifies and extends the initial signal.

Stability Characteristics#

Kisspeptin-54 is supplied as a lyophilized powder for research and clinical applications. Key stability considerations include:

• Storage: Lyophilized kisspeptin should be stored at -20 degrees C or below for long-term stability. Once reconstituted, solutions should be stored at 2-8 degrees C and used within a defined timeframe, typically within days for research preparations
• pH sensitivity: Kisspeptin is most stable in neutral to slightly acidic pH ranges (pH 5-7). Strongly alkaline conditions accelerate degradation through base-catalyzed hydrolysis of the amide bond
• Protease sensitivity: As a natural peptide substrate, kisspeptin is readily degraded by serum proteases, necessitating the use of protease inhibitor cocktails when measuring circulating levels in biological samples
• Oxidation: The presence of tryptophan (Trp) and methionine residues in KP-54 renders the peptide susceptible to oxidative degradation under prolonged light exposure or in the presence of oxidizing agents

The short half-life and protease sensitivity of native kisspeptin have motivated ongoing research into metabolically stable kisspeptin analogs, including peptides with D-amino acid substitutions, backbone modifications, and non-peptide small-molecule KISS1R agonists, though none have yet advanced to clinical validation.

Related Reading#

• Kisspeptin overview and research guide
• Peptides similar to Kisspeptin
• Kisspeptin research evidence